$72.210
+2.260 (+3.13%)收盘时
UTMD 收入构成
Utah Medical Products Inc (UTMD) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Gynecology/Electrosurgery/Urology, accounting for 50.2% of total sales, equivalent to $4.28M. Other significant revenue streams include Neonatal and Blood Pressure Monitoring and Accessories. Understanding this composition is critical for investors evaluating how UTMD navigates market cycles within the Medical Equipment, Supplies & Distribution industry.
UTMD 盈利能力与利润率
Evaluating the bottom line, Utah Medical Products Inc maintains a gross margin of 56.14%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 32.42%, while the net margin is 32.33%. These profitability ratios, combined with a Return on Equity (ROE) of 8.81%, provide a clear picture of how effectively UTMD converts its operational activities into shareholder value.
UTMD 同业对比
In the context of the broader market, UTMD competes directly with industry leaders such as ELMD and TLSI. With a market capitalization of $229.63M, it holds a significant position in the sector. When comparing efficiency, UTMD's gross margin of 56.14% stands against ELMD's 78.71% and TLSI's 86.78%. Such benchmarking helps identify whether Utah Medical Products Inc is trading at a premium or discount relative to its financial performance.
Utah Medical Products Inc 财务表现
The company has shown stable financial performance with a gross margin of 56.14% in the latest quarter and a net margin of 32.33%. However, total revenue has declined by 10.2% year-over-year in Q1, raising concerns about market demand.
Financials
相关文章
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。